1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
Sino Biopharmaceutical Limited

Sino Biopharmaceutical Limited

SBMFF
Sino Biopharmaceutical LimitedUS flagOther OTC
0.64
USD
- -
- -
11.35BMarket Cap
Sino Biopharmaceutical Limited
SBMFF
(Other OTC)

Recent

price

0.64

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.21
0.28
0.36
0.46
0.59
0.73
0.81
0.89
1.13
1.29
1.26
1.43
1.4
1.41
1.58
1.77
1.35
Revenue per Share
0.03
0.02
0.04
0.05
0.07
0.09
0.1
0.13
0.49
0.15
0.15
0.78
0.14
0.13
0.19
0.13
0.53
Basic EPS, GAAP
0.01
0.04
0.05
0.05
0.08
0.05
0.13
0.14
0.18
0.19
0.18
0.19
0.24
0.24
0.29
0.42
- -
Free Cash Flow per Basic Share
0.02
0.02
0.01
0.01
0.02
0.01
0.02
0.03
0.04
0.04
0.06
0.05
0.07
0.03
0.1
0.08
- -
Dividend per Share
0.1
0.09
0.11
0.14
0.19
0.26
0.33
0.01
0.02
0.01
0.02
1.25
1.26
1.3
1.4
1.41
0.02
Book Value per Share
0.22
0.23
0.27
0.33
0.41
0.51
0.62
0.74
0.79
0.95
1.14
1.92
1.93
1.9
2.17
1.95
1.56
Tangible Book Value per Share
16,383
16,712
16,677
16,677
16,677
16,677
16,677
16,677
18,549
18,811
18,800
18,769
18,622
18,529
18,294
18,002
18,781
Basic Weighted Avg Shares
3,482
4,680
6,036
7,737
9,898
12,184
13,543
14,819
20,889
24,234
23,647
26,861
26,026
26,199
28,866
31,834
25,353
Sales/Revenue/Turnover
26.79
16.39
18.49
17.8
18.43
19.55
20.38
22.01
20.68
21.45
18.2
16.21
21.05
23.23
21.94
21.67
19.82
Operating Margin (%)
73
110
144
175
207
296
317
343
1,176
1,446
1,655
993
1,047
1,074
1,321
1,212
- -
Depreciation Expense
483
375
717
810
1,210
1,489
1,637
2,171
9,046
2,762
2,771
14,608
2,544
2,332
3,500
2,343
10,038
Net Income, GAAP
20.98
16.72
17.71
16.59
15.71
15.47
14.83
12.92
6.09
15.86
13.41
10.54
13.36
14.74
9.34
23.46
10.95
Effective Tax Rate (%)
13.87
8
11.88
10.47
12.22
12.22
12.09
14.65
43.31
11.4
11.72
54.38
9.77
8.9
12.12
7.36
39.59
Profit Margin (%)
2,501
1,698
2,257
2,537
3,454
3,697
7,076
8,092
8,798
16,790
11,851
8,158
5,784
1,199
5,129
9,266
12,328
Working Capital
108
28
16
- -
1,030
257
1,679
2,210
555
7,926
12,628
5,532
4,258
1,373
2,080
7,651
11,807
LT Debt
3,666
3,866
4,658
5,646
7,051
8,742
10,678
12,611
17,779
20,561
22,420
37,729
37,944
38,170
42,774
42,086
31,109
Total Equity
22.55
16.35
20.94
21.62
21.22
21.12
19.24
18.88
21.59
17.15
11.23
8.94
9.27
10.03
11.02
9.41
8.82
Return on Invested Capital (%)
33.95
3.69
11.42
6.84
11.04
8.34
6.33
8.47
99.69
8.06
8.51
40.66
1.03
-0.03
1.99
-0.84
36.7
Return on Capital (%)
30.58
24.03
42.02
37.79
43.15
39.76
33.44
76.47
4,030.64
991.05
798.19
122.23
10.83
9.81
14.07
9.18
2,892.08
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'20
Mar'21
Jun'21
ST Debt
1,582
1,225
1,846
LT Borrowings
12,363
12,317
11,516
LT Finance Leases
265
264
291
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
18,861
18,861
18,861
Market Capitalization
120,331
119,405
116,934

Working Capital

FRC

•

in mil. unless spec.
Dec'20
Mar'21
Jun'21
Total Current Assets
22,794
21,791
23,813
Cash, Cash Equivalents & STI
16,432
10,337
10,443
Accounts Receivable, Net
2,248
3,251
5,059
Inventories
1,880
1,813
1,732
Total Current Liabilities
10,944
10,358
11,485
Payables & Accruals
- -
- -
- -
ST Debt
1,582
1,225
1,846
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
18.58%
15.98%
-1.61%
Free Cash Flow
31.52%
18.44%
45.35%
Net Income, GAAP
64.34%
70.66%
-33.04%
Sales/Revenue/Turnover
10.68%
6.32%
10.28%
Total Cash Common Dividend
32.64%
27.45%
-18.62%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
26,199
2024
- -
- -
- -
- -
28,866
2025
- -
- -
- -
- -
31,834

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.13
2024
- -
- -
- -
- -
0.19
2025
- -
- -
- -
- -
0.13

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.03
2024
- -
- -
- -
- -
0.1
2025
- -
- -
- -
- -
0.08
Similar Companies
Emergent BioSolutions Inc. (0IGA.L)
Legend Biotech Corporation (LEGN)
OncoCyte Corporation (OCX)
Field Trip Health & Wellness Ltd. (FTHWF)
Starpharma Holdings Limited (SPHRF)
Stemcell Holdings, Inc. (STMM)
Business
Sino Biopharmaceutical Limited researches, develops, manufactures and markets biopharmaceutical products, with a focus on innovative drugs and biosimilars across oncology, liver/metabolic diseases, respiratory conditions and surgery/analgesia therapies. The company operates through segments including Modernised Chinese Medicines and Chemical Medicines, Investment, and Others; its core products encompass oncology medicines such as Focus V (Anlotinib Hydrochloride Capsules), Annike (Penpulimab Injection), Yilishu (Efbemalenograstim alfa Injection), Andewei (Benmelstobart Injection), Anboni (Unecritinib Fumarate Capsules), Anluoqing (Envonalkib Citrate Capsules), Anfangning (Garsorasib Tablets), Anbeisi (Bevacizumab Injection), Delituo (Rituximab Injection), Saituo (Trastuzumab for Injection) and Paletan (Pertuzumab Injection); liver/metabolic disease medicines including Tianqing Ganmei (Magnesium Isoglycyrrhizinate Injection) and Runzhong (Entecavir Dispersible Tablets); respiratory medicines such as Tianqing Suchang (Budesonide Suspension for Inhalation), Tianyun (Colistimethate Sodium for Injection) and Deruituo (Tulobuterol Patches); and surgery/analgesia medicines like Zepolas/Debaian (Flurbiprofen Cataplasms), Kailitong (Limaprost Tablets), Anhengji (Recombinant Human Coagulation Factor VIII for Injection), Putanning (Meloxicam Injection (II)), Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection) and Deshuping (Loxoprofen Sodium Cataplasms). Founded in 2000 and headquartered in Hong Kong at Unit 09, 41st Floor, Office Tower, Convention Plaza, 1 Harbour Road, Wanchai, the company maintains principal operations in mainland China through subsidiaries including Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Beijing Tide Pharmaceutical Co., Ltd., Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd., Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. and Jiangsu Chia Tai Qingjiang Pharmaceutical Co., Ltd., with manufacturing sites compliant with NMPA GMP standards for injections, capsules, tablets and other forms. Sino Biopharmaceutical targets hospitals, clinics and healthcare providers primarily in China, with expanding international efforts through partnerships and R&D collaborations; it reports robust innovative product sales growth, reaching RMB7.8 billion in the first half of 2025, representing 44.4% of total revenue. Recent developments include the full acquisition of LaNova Medicines in July 2025 for up to US$951 million (net US$500 million after prior stake), enhancing oncology capabilities with PD-1xVEGF bispecific assets previously partnered with Merck and AstraZeneca; an exclusive licensing deal with Phrontline Biopharma in October 2025 for TJ101 in mainland China and Hong Kong SAR; NMPA approvals for two innovative products, Putanning (Meloxicam Injection II) and Anqixin (Recombinant Human Coagulation Factor VIIa N01 for Injection); and five generic drug approvals, alongside Phase III advancements for candidates like TQB3616 (CDK2/4/6 inhibitor), TQ05105 (JAK/ROCK inhibitor) and LM-302 (Claudin 18.2 ADC).

Company News

APIChatGPT

  • reuters.com

    Sino Biopharmaceutical, GSK expand alliance with China rights to respiratory drugs

  • wsj.com

    AstraZeneca, Sino Biopharm Sign Up to $1.9 Billion Respiratory Drug Licensing Deal

  • reuters.com

    Hong Kong-listed Sino Biopharma, AstraZeneca sign respiratory drug deal worth up to $1.9 billion

  • reuters.com

    Sino Biopharmaceutical to divest 67% stake in unit CP Qingdao for $253 mln

  • forbes.com

    Chinese Company Gets FDA Approval For Drug To Fight Chemotherapy Nausea